Clinical trials: Respiratory Symptoms
Pulmonary Disease, Chronic Obstructive
Tiotropium (18 Mcg) Once Daily Via the HandiHaler® in Patients With Chronic Obstructive Pulmonary Disease (COPD)
The primary objective of this trial is to determine whether treatment with tiotropium (18 mcg) capsule once daily via the HandiHaler reduces the proportion of patients with COPD experiencing an exacerbation and the proportion of…
- Trial name
- NCT00274547
- Testing
- Tiotropium
- Where
- 26 sites in United States
- Volunteers
- 1,829 people
- Sponsor
- Boehringer Ingelheim
COPD
Effect of Indacaterol on Inspiratory Capacity and Lung Function in Patients With COPD Versus Placebo and Formoterol
The purpose of this study is to assess the change in inspiratory capacity and lung function in patients with chronic obstructive pulmonary disease when treated with indacaterol compared to placebo and formoterol.
- Trial name
- NCT00422552
- Testing
- Indacaterol (QAB149)
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- Novartis
Pulmonary Disease, Chronic Obstructive
Effect of Spiriva® on Health-related Quality of Life in Chronic Obstructive Pulmonary Disease (COPD) Patients Who Stopped Smoking During Treatment.
Post marketing Surveillance to gain insights into the effects of therapy with Spiriva® (tiotropium bromide) on health-related quality of life in COPD patients who stopped smoking during treatment and to obtain safety data…
- Trial name
- NCT02172547
- Testing
- Spiriva
- Volunteers
- 10,821 people
- Sponsor
- Boehringer Ingelheim
Allergic Rhinitis, Allergic Rhinoconjunctivitis
Demonstration of an Anti-allergic Effect in Subjects Treated With Callergin Nasal Spray in Comparison to Untreated Subjects and Subjects Treated With Vis Alpin® Alpensalz Nasal Spray, All Suffering From Grass Pollen Induced Rhinitis/Rhinoconjunctivitis
Allergic rhinitis (AR) in its seasonal and perennial form is a common allergic condition. The majority of allergic rhinitis sufferers report nasal (congestion, sneezing, itching and rhinorrhea) and ocular (redness, watery eyes…
- Trial name
- NCT04531358
- Testing
- nasal spray, no treatment
- Where
- Austria
- Volunteers
- 42 people
- Sponsor
- Marinomed Biotech AG
Pulmonary Disease, Chronic Obstructive
Postmarketing Surveillance Study of Atrovent® in Chronic Obstructive Airways Disease
Study to obtain further information on the tolerability and efficacy of Atrovent® unit dose vial 500 µg in the treatment of Chronic Obstructive Airways Disease under conditions of daily practice
- Trial name
- NCT02236715
- Testing
- Atrovent®
- Volunteers
- 1,039 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
A 2 Part Study Examining Doses Of GSK961081 In Healthy Volunteers And Then In COPD Patients
GSK961081 has previously been administered to healthy subjects in a nebulised formulation and the first part of this study which will be conducted in healthy subjects proposes to bridge the change from nebulised to DPI…
- Trial name
- NCT00478738
- Testing
- GSK961081
- Where
- 5 sites in Germany, South Africa
- Volunteers
- 82 people
- Sponsor
- GlaxoSmithKline
Long COVID
Study of LAU-7b for the Treatment of Long COVID in Adults
ESSOR is a double-blind, placebo-controlled study of the orally-administered antiviral and inflammation-controlling LAU-7b for the treatment of adults with Long COVID and moderate to severe symptoms.
- Trial name
- ESSOR (NCT05999435)
- Testing
- LAU-7b for 3 cycles
- Where
- 5 sites in Canada
- Volunteers
- 272 people
- Sponsor
- Laurent Pharmaceuticals Inc.
Migraine Disorders
Occipital Nerve Stimulation (ONS) for Migraine: OPTIMISE
The primary objective of this study is to evaluate the safety and efficacy of occipital nerve stimulation (ONS) using the Boston Scientific Corporation (BSC) Precision™ System in the management of intractable chronic migraine…
- Trial name
- OPTIMISE (NCT01775735)
- Testing
- Occipital nerve stimulator
- Where
- 10 sites in United States
- Volunteers
- 28 people
- Sponsor
- Boston Scientific Corporation
Covid19
A Pilot Study for the Collection Of Vocalized, Individual Digital Cough Sound Recordings to Screen for COVID-19
Decentralized clinical study designed to collect cough sounds and self-reported symptoms alongside a COVID-19 realtime quantitative polymerase chain reaction (rt-qPCR) test.
- Trial name
- COVID-Cough (NCT04864535)
- Testing
- Recordings of cough sounds from adults
- Where
- United States
- Volunteers
- 1,500 people, healthy volunteers welcome
- Sponsor
- ResApp Health Limited
Changes in Gut Microbiota, Gut Metabolites, Respiratory Symptoms, and Well-being Index
A Probiotic for Health Outcomes in Short-Term Overseas Travel
With the improvement of living standards, travel has become a common form of leisure. However, travelers often face changes in living environments, dietary habits, and sleep schedules, all of which can impact the gut microbiota…
- Trial name
- NCT07705659
- Testing
- Bifidobacterium longum, Maltodextrin
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- DiproBio (Shanghai) Co., Ltd.
Chronic Obstructive Pulmonary Disease
Oxis 9mcg Turbuhaler Clinical Experience Investigation
The purpose of the investigation is to confirm the ADR development and the contributing factors possibly having an impact on the safety under the post-marketing actual use of Oxis 9 mcg Turbuhaler.
- Trial name
- NCT01749462
- Where
- 41 sites in Japan
- Volunteers
- 398 people
- Sponsor
- AstraZeneca
COPD
Efficacy of AZD3199 in Chronic Obstructive Pulmonary Disease (COPD) Patients
The purpose of this study is to investigate the efficacy, safety and tolerability of 4 weeks treatment with AZD3199 in moderate to severe COPD.
- Trial name
- GLAD (NCT00929708)
- Testing
- AZD3199, formoterol
- Where
- 38 sites in Bulgaria, Canada and 3 more
- Volunteers
- 329 people
- Sponsor
- AstraZeneca
Rhinitis, Allergic
Ability of a Cat Food to Reduce Respiratory Symptoms in Cat Allergic Patients
Cat allergy is the most common animal allergy, affecting approximately 1 in 5 adults worldwide. The prevalence of allergy to furry animals is increasing, and cat allergy is a major risk factor for the development of asthma and…
- Trial name
- CATS (NCT05656482)
- Testing
- Cats fed with PRO PLAN® LIVECLEAT®
- Where
- France
- Volunteers
- 50 people
- Sponsor
- MASK-air SAS
SARS-CoV2 Infection
Efficacy and Safety of EXOSOME-MSC Therapy to Reduce Hyper-inflammation In Moderate COVID-19 Patients
In COVID-19 infection caused by the Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), there is a dysregulation of the immune system response that causes cytokine storm syndrome.
- Trial name
- EXOMSC-COV19 (NCT05216562)
- Testing
- Exosome-MSC Intravenous injection, COVID-19 Standard Treatment
- Where
- 3 sites in Indonesia
- Volunteers
- 60 people
- Sponsor
- Dermama Bioteknologi Laboratorium
Pulmonary Disease, Chronic Obstructive
General Practice Quality Assurance Project. Chronic Obstructive Pulmonary Disease (COPD) Diagnosis and Treatment
A Cross sectional observational Quality Assurance Project in General Practice to COPD Diagnosis and Treatment
- Trial name
- NCT00319813
- Testing
- Education
- Volunteers
- 8,000 people
- Sponsor
- Boehringer Ingelheim
Hypoxia
OM2 Motion Verification Study
The verification of an investigational pulse oximetry board to verify pulse rate and saturation accuracy over a specified saturation range in diverse populations.
- Trial name
- NCT06415786
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Medtronic - MITG
Pulmonary Disease, Chronic Obstructive, Bronchitis, Chronic
Safety and Efficacy of 4-weeks Treatment of BIBW 2948 BS in Patients With Chronic Obstructive Bronchitis
The primary objective of this study is to investigate the effect of 4-week treatment with 7.5 mg b.i.d, 15 mg q.d and 15 mg b.i.d.
- Trial name
- NCT00726479
- Testing
- BIBW 2948 BS
- Where
- 24 sites in United States, France and 1 more
- Sponsor
- Boehringer Ingelheim
Metastases, Neoplasm, Carcinoma, Non-small Cell Lung
A Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid Tumors
Study I3G-MC-JGCB (JGCB) is a multicenter, nonrandomized, open-label, dose-escalation Phase 1b study of LY2584702 in combination with either erlotinib or everolimus.
- Conditions
- Metastases, Neoplasm, Carcinoma, Non-small Cell Lung, Renal Cell Carcinoma, Neuroendocrine Tumors
- Trial name
- NCT01115803
- Testing
- LY2584702, Erlotinib, Everolimus
- Where
- 3 sites in United States, France
- Volunteers
- 29 people
- Sponsor
- Eli Lilly and Company
Quality of Life, Fatigue
Complementary Treatment of PG2 to Improve Clinical Benefit Response and Quality of Life in Fatigue
The objective of this study is to evaluate the efficacy and safety of PG2 as a complementary treatment to conventional chemotherapy among NSCLC patients.
- Conditions
- Quality of Life, Fatigue, Complementary
- Trial name
- NCT00518869
- Testing
- PG2
- Where
- 10 sites in Taiwan
- Volunteers
- 13 people
- Sponsor
- PhytoHealth Corporation
Chronic Obstructive Pulmonary Disease (COPD)
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
The purpose of the study is to provide long term safety data of NVA237. This study will assess the safety and tolerability of a single dose strength of NVA237.
- Trial name
- NCT01697696
- Testing
- NVA237, Long-acting beta 2-agonist (LABA)
- Where
- 61 sites in United States
- Volunteers
- 511 people
- Sponsor
- Novartis Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.